Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation-Reference-Cited by-同舟云学术

Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation

Published:2021-05-26 Issue:595 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Li Jianneng¹^ORCID,Berk Michael¹^ORCID,Alyamani Mohammad¹^ORCID,Sabharwal Navin¹,Goins Christopher²,Alvarado Joseph²,Baratchian Mehdi¹,Zhu Ziqi¹^ORCID,Stauffer Shaun²,Klein Eric A.¹³^ORCID,Sharifi Nima¹³⁴^ORCID

Affiliation:

1. Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

2. Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

3. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

4. Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Abstract

Inhibiting H6PD restores prostate cancer response to AR antagonists by normalizing glucocorticoid metabolism in mouse xenograft models.

Funder

National Cancer Institute

Prostate Cancer Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference40 articles.

1. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

2. Androgen Signaling in Prostate Cancer

3. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

4. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

5. Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalk;Frontiers in Endocrinology;2024-07-04

2. Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations;Cancers;2024-01-29

3. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer;Nucleic Acids Research;2023-11-28

4. Combining glycolysis and oxidative stress characterizations to assess prognosis in ovarian cancer;2023-11-14

5. Targeting the Androgen Signaling Axis in Prostate Cancer;Journal of Clinical Oncology;2023-09-10